"to serve" in Finnish
Palvella is committed to serving patients with serious, debilitating rare, genetic diseases through the development and commercialization of life-changing, pathogenetically targeted therapies.
The company was founded with the single-minded goal of serving individuals suffering from rare diseases by developing safe and efficacious therapies that will dramatically enhance their quality of life. The Palvella team is committed to recruiting passionate and like-minded collaborators to ensure we expeditiously deliver on this important mission for rare disease patients.
Palvella is backed by leading biopharmaceutical investors including biotechnology venture capital firms, BioAdvance and Agent Capital, as well as Ligand Pharmaceuticals.